Skip to main content
William Tap, MD, Oncology, New York, NY, Memorial Sloan-Kettering Cancer Center

WilliamDTapMD

Oncology New York, NY

Associate Member, Memorial Sloan Kettering Cancer Center

Overview of Dr. Tap

Dr. William Tap is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice 17 years. Dr. Tap accepts several types of health insurance, listed below. He is one of 416 doctors at Memorial Sloan-Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Internal Medicine, 2000 - 2003
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2000

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NJ State Medical License
    NJ State Medical License 2020 - 2023
  • NY State Medical License
    NY State Medical License 2011 - 2024
  • CA State Medical License
    CA State Medical License 2003 - Present
  • TN State Medical License
    TN State Medical License 2002 - 2004
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2014
  • Top Doctors: New York Metro Area Castle Connolly, 2013-2014
  • America's Top Doctors for Cancer Castle Connolly, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial gia... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • ANNOUNCE: Combination of Olaratumab and Doxorubicin Versus Doxorubicin Alone in Patients with Advanced Soft Tissue Sarcomas
    ANNOUNCE: Combination of Olaratumab and Doxorubicin Versus Doxorubicin Alone in Patients with Advanced Soft Tissue SarcomasJune 6th, 2019
  • Adding Olaratumab to Chemo Improves Survival in Soft Tissue Sarcoma
    Adding Olaratumab to Chemo Improves Survival in Soft Tissue SarcomaDecember 4th, 2015
  • Old Greenwich Dad Teams up with Friend for Coast-to-Coast Bike Trip 'To Continue His Son's Legacy'
    Old Greenwich Dad Teams up with Friend for Coast-to-Coast Bike Trip 'To Continue His Son's Legacy'August 12th, 2021
  • Join now to see all

Hospital Affiliations

Insurance Accepted

  • BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    Health Net Oregon PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment